Dr. Douglas Warner, M.D., is a distinguished medical professional who currently holds the position of Chief Medical Officer at TYRA Biosciences Inc., a company focused on developing precision medicines for cancer and other diseases. Dr. Warner brings a wealth of experience and expertise to his role, having spent over two decades in the field of oncology and clinical development. Prior to joining TYRA Biosciences, he held leadership positions at several prominent pharmaceutical companies, including Novartis and Genentech, where he was instrumental in the development and approval of multiple oncology drugs. Throughout his career, Dr. Warner has been recognized for his contributions to the field of oncology. He has authored numerous peer-reviewed articles and has been an invited speaker at various international conferences. His research interests include targeted therapies and immuno-oncology, areas in which he has made significant strides. At TYRA Biosciences, Dr. Warner leads the clinical development team, overseeing the design and execution of clinical trials for the company's pipeline of precision medicine candidates. His strategic vision and deep understanding of the oncology landscape are pivotal in advancing TYRA's mission to bring innovative treatments to patients in need. In addition to his professional accomplishments, Dr. Warner is committed to mentoring the next generation of medical professionals. He has served on the faculty of several prestigious medical institutions, where he has trained and inspired numerous medical students and residents. His dedication to education and patient care, combined with his leadership at TYRA Biosciences, positions him as a key figure in the ongoing fight against cancer.